Fasiplon
Fasiplon (RU 33203) is a nonbenzodiazepine anxiolytic drug from the imidazopyrimidine family of drugs.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H15N5O2 |
Molar mass | 273.296 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Fasiplon binds strongly to benzodiazepine sites on the GABAA receptor and has similar anxiolytic effects in animals, but with less sedative or muscle relaxant action.[1] It was developed by a team at Roussel Uclaf in the 1990s[2]
References
- Tully WR, Gardner CR, Gillespie RJ, Westwood R (July 1991). "2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors". Journal of Medicinal Chemistry. 34 (7): 2060–7. doi:10.1021/jm00111a021. PMID 1648620.
- US Patent 5869481 Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.